pharmaphorum

JANUARY 5, 2022

Teliso-V (telisotuzumab vedotin) is pitching to become the first targeted cancer treatment for people with non-small cell lung cancer (NSCLC) whose tumours overexpress c-Met. The post FDA gives AbbVie’s c-Met lung cancer ADC a breakthrough tag appeared first on. Preliminary results from that study showed a 53.8%

Antibody 111

Antibody Drugs Protein Gene 111

pharmaphorum

DECEMBER 23, 2021

The designation – which is awarded to therapies that could represent a significant improvement over standard of care in either efficacy, safety, or both – has been awarded on the strength of phase 1 results in patients with metastatic or locally advanced EGFR-mutated non-small cell lung cancer (NSCLC).

Drugs 72

Drugs Antibody Clinical Trials Clinical Trials 72

Rethinking Clinical Trials

MARCH 1, 2023

S1800A was a Phase II randomized study of ramucirumab plus pembrolizumab versus standard of care for NSCLC patients previously treated with immunotherapy performed within the Lung-MAP platform. Overall survival was significantly improved with a hazard ratio of 0.69, median OS of 14.5

Clinical Trials 130

Clinical Trials Clinical Trials Trials Packaging 130

pharmaphorum

JANUARY 5, 2021

The FDA’s breakthrough status is for tiragolumab plus Tecentriq is the first for a TIGIT drug, and covers the first-line treatment of patients with advanced-stage non-small cell lung cancer (NSCLC) that expresses high levels of PD-L1. The post Roche nabs breakthrough tag for TIGIT cancer immunotherapy appeared first on.

Immune Response 52

Immune Response FDA Approval Drugs Sales 52

pharmaphorum

APRIL 27, 2022

.” AZ and Daiichi Sankyo have previously been awarded breakthrough designations for Enhertu as a treatment for second- and later-line therapy of HER2-positive breast cancer, as well as HER2-positive non-small cell lung cancer (NSCLC) and gastric cancer.

Sales 59

Sales Drugs Antibody Licensing 59

pharmaphorum

JULY 25, 2022

That alliance also yielded $6 billion blockbuster Darzalex as well as Rybrevant (amivantamab), J&J’s first bispecific antibody which is used to treat EGFR-mutated non-small cell lung cancer (NSCLC). Tecvayli previously scored a priority medicines (PRiME) designation from the EMA and a breakthrough-therapy tag from the FDA.

Antibody 52

Antibody Medicine Drugs Trials 52

Delveinsight

FEBRUARY 23, 2021

The company plans to use the capital to expand its pipeline of protein-based vaccines and biologic cancer therapies utilizing its innovative and proprietary Trimer-Tag technology platform. M LightDeck for SARS-CoV-2 antigen test; Libtayo for first-line advanced NSCLC subset appeared first on DelveInsight Business Research.

In-Vitro 52

In-Vitro Vaccination Vaccine Licensing 52